BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) ( www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that a scientific poster presented at the Society of Interventional Radiology (SIR) conference, featuring data generated using the MicroThermX ® Microwave Ablation System (MicroThermX ®), demonstrated a significant advantage for MicroThermX ® microwave ablation. The study, "Impact of Variation in Portal Venous Blood Flow on the Size of Radiofrequency and Microwave Ablation Lesions," was conducted by Gerald D. Dodd, III, MD, Nicolas A. Dodd, and Anthony C. Lanctot, MS, Department of Radiology, University of Colorado, School of Medicine. Dr. Gerald D. Dodd, one of the pioneers in Radiofrequency (RF) ablation, presented the data from the in-vitro study, which was designed to assess the impact of variations in blood flow on ablation zones produced using the microwave MicroThermX ® compared to a commercially available RF system. The presentation received an award at the SIR conference.
"Microwave ablation is able to deliver a predictable and reproducible heating pattern that is not influenced by physiological changes in blood flow in the liver," said Dr. Gerald D. Dodd. "This is a significant clinical advantage over RF ablation, which is significantly impacted by physiological changes in blood flow in the liver. Predictable and reproducible ablations are a critical element of treatment planning for ablation. Not knowing the size of the ablation that you are going to get when treating a liver tumor leads to both over-treatment and under-treatment. Over-treatment poses the risk of injury to adjacent vital structures, and under-treatment means you didn't 'kill' the tumor. The predictable and reproducible performance of microwave ablation should translate to improved clinical results for cancer patients."
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for many years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.